Awareness of the severity of liver disease re-examined using softwarecombined biomarkers of liver fibrosis and necroinflammatory activity

BMJ Open

Volumn 5, Issue 12, 2015, Pages

  Poynard, Thierry ^a,b   Deckmyn, Olivier ^c   Munteanu, Mona ^c   Ngo, Yen ^c   Drane, Fabienne ^c   Castille, Jean Marie ^c   Housset, Chantal ^b   Ratziu, Vlad ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Biopredictive   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER;

AGED; ANTIVIRAL THERAPY; ARTICLE; AWARENESS; COMPUTER PROGRAM; DISEASE SEVERITY ASSESSMENT; FEMALE; FRANCE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH CAMPAIGN; REIMBURSEMENT; RETROSPECTIVE STUDY; SCREENING; UNITED STATES; ADULT; BLOOD; COMPARATIVE STUDY; COMPLICATION; COMPUTER ASSISTED DIAGNOSIS; DISEASE COURSE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOFTWARE; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOMARKERS; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE PROGRESSION; FEMALE; FRANCE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOFTWARE; UNITED STATES;

EID: 84960103467     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010017     Document Type: Article

References (52)

1. US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries and risk factors. JAMA 2013;310:591-608.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
3. [No authors listed]. The price of good health. Nat Med 2014;20:319.
4. Poynard T. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2011;54:586-7.
5. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807-20.
6. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64. Connected 23 April 2015.
7. Kuehn BM. Guideline: new HCV drugs should go to sickest patients. JAMA 2014;312:1084-5.
8. AASLD guidelines: http://www.hcvguidelines.org/full-report/ hcv-testing-and-linkage-care (accessed 19 Apr 2015).
9. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
10. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157:817-22.
11. Afdhal NH, Zeuzem S, Schooley RT, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20:745-60.
12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
13. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis. Lancet 1997;349:825-32.
14. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
15. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75.
16. Poynard T, Munteanu M, Ngo Y, et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol 2010;34:388-96.
17. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FT. A reappraisal at 7 years of age. BMC Gastroenterol 2011;11:39.
18. Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010;15:617-31.
19. Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS ONE 2014;9:e100182.
20. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
21. Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FT, ActiTest, SteatoTest and NashTest in patients with severe obesity: meta-analysis of individual patient data. PLoS ONE 2012;7: e30325.
22. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FT) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol 2012;57:541-8.
23. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FT® ) and elastography (FibroScan® ). J Hepatol 2014;61:994-1003.
24. Poynard T, Vergniol J, Ngo Y, et al. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FT™) and transient elastography (FibroScan® ). J Hepatol 2014;60:706-14.
25. Perazzo H, Munteanu M, Ngo Y, et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment Pharmacol Ther 2014;40:1081-93.
26. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers. BMC Gastroenterol 2010;10:40.
27. Zelber-Sagi S, Ratziu V, Zvibel I, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 2012;24:262-9.
28. Salles N, Dussarat P, Foucher J, et al. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients. Gastroenterol Clin Biol 2009;33:126-32.
29. Grattagliano I, Ubaldi E, Napoli L, et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study. Ann Hepatol 2013;12:70-7.
30. Jacqueminet S, Lebray P, Morra R, et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 2008;6:828-31.
31. de Lédinghen V, Vergniol J, Gonzalez C, et al. Screening for liver fibrosis by using FibroScan(® ) and FibroTest in patients with diabetes. Dig Liver Dis 2012;44:413-18.
32. Petit JM, Guiu B, Masson D, et al. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver Int 2011;31:1332-6.
33. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007; 25:207-18.
34. Poynard T, Ratziu V, Benhamou Y, et al. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005;128:1146-8.
35. Fontaine H, Petitprez K, Roudot-Thoraval F, et al. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007;31:504-9.
36. Castera L, Denis J, Babany G, et al. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol 2007;46:528-9.
37. l\'Association Française pour l\'Etude du Foie. Hepatitis B: the French point of view on EASL guidelines. Gastroenterol Clin Biol 2009;33:535-8.
38. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2071-94.
39. Poynard T, Lenaour G, Vaillant JC, et al. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol 2012;10:657-63.
40. Rüeger S, Bochud PY, Dufour JF, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2015;64:1605-15.
41. Eslam M, Hashem AM, Leung R, et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015;6:6422.
42. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61: S45-57.
43. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82.
44. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008;28:705-12.
45. Udompap P. Advanced fibrosis is common in individuals whose hepatitis C has not been diagnosed: results from the National Health and Nutrition Examination Survey 2001-2012. EASL. April 22-26 2015, Vienna, Austria.
46. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302.
47. Holmberg SD, Lu M, Rupp LB, et al., Chronic Hepatitis Cohort Study (CHeCS) Investigators. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013;57:240-6.
48. Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70.
49. Chao DT, Lim JK, Ayoub WS, et al. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther 2014;39:349-58.
50. Mehta SH, Lau B, Afdhal NH, et al. Exceeding the limits of liver histology markers. J Hepatol 2009;50:36-41.
51. Houot M, Ngo Y, Munteanu M, et al. Systematic review with metaanalysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther Published Online First: 30 Oct 2015. doi:10.1111/apt.13446.
52. Liu S, Schwarzinger M, Carrat F, et al. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE 2011;6:e26783.